[1]
|
Phani, S., Loike, J.D. and Przeborski, S. (2012) Neurodegeneration and inflammation in Parkinson desease. Parkinsonism & Related Disorders, 18, S207-S209.
doi:10.1016/S1353-8020(11)70064-5
|
[2]
|
Streit, W.J., Mrak, R.E. and Griffin, W.S.T. (2004) Microglia and neuroinflammation: A pathological perspective. Journal of Neuroinflammation, 1, 14.
http://www.jneuroinflammation.com/content/1/1/14
doi:10.1186/1742-2094-1-14
|
[3]
|
McGeer, P.L., Schwab, C., Parent, A. and Doudet, D. (2003) Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Annals of Neurology, 54, 599-604.doi:10.1002/ana.10728
|
[4]
|
Nagatsu, T., Mogi, M., Ichinose, H. and Togari, A. (2000) Cytokines in Parkinson’s disease. Journal of Neural Transmission. Supplement, 58, 143-151.
|
[5]
|
Blum-Degen, D., Muller, T., Kuhn, W., Gerlach, M., Przuntek, H. and Riederer, P. (1995) Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neuroscience Letters, 202, 17-20.
doi:10.1016/0304-3940(95)12192-7
|
[6]
|
Mogi, M., Harada, M., Riederer, P., Narabyashi, H., Fujita. J. and Nagatsu, T. (1994) Interleukin-1 beta growth factor and transforming growth factor-alpha are elevated in the brain from Parkinsonian patients. Neuroscience Letters, 180, 147-150.
doi:10.1016/0304-3940(94)90508-8
|
[7]
|
Muller, T., Blum-Degen, D., Przuntek, H. and Kuhn, W. (1998) Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson’s disease. Acta Neurologica Scandinavica, 98, 142-144.
doi:10.1111/j.1600-0404.1998.tb01736.x
|
[8]
|
Knott, C., Stern, G. and Wilkin, G.P. (2000) Inflammatory regulators in Parkinson’s disease: iNOS, lipocortin-1, and cyclooxygenase-1 and -2. Molecular and Cellular Neuroscience, 16, 724-739. doi:10.1006/mcne.2000.0914
|
[9]
|
Gao, X., Chen, H., Schwarzchild, M.A. and Ascherio, A. (2011) Use of ibuprofen and risk of Parkinson’s disease. Neurology, 76, 863-869.
doi:10.1212/WNL.0b013e31820f2d79
|
[10]
|
Hirsch, E.C. and Hunnot, S. (2009) Neuroinflammation in Parkinson’s disease: A target for neuroprotection? The Lancet Neurology, 8, 382-397.
doi:10.1016/S1474-4422(09)70062-6
|
[11]
|
Qin, L., Wu, X., Block, M.L., Liu, Y., Breese, G.R., Hong, J.S., et al. (2007) Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia, 55, 453-462.doi:10.1002/glia.20467
|
[12]
|
Kim, W.G., Mohney, R.P., Wilson, B., Jeohn, G.H., Liu, B. and Hong, J.S. (2000) Regional difference in susceptibility to lipopolysacchride-induced neurotoxicity in the rat brain: Role of microglia. The Journal of Neuroscience, 20, 6309-6316.
|
[13]
|
Lieberman, A.P., Pitha, P.M., Shin, H.S. and Shin, M.L. (1989) Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proceedings of the National Academy of Sciences of the United States of America, 86, 6348-6352. doi:10.1073/pnas.86.16.6348
|
[14]
|
Chang, Y.C., Kim, H.-W., Rapoport, S.I. and Rao, J.S. (2008) Chronic NMDA administration increases neuroinflammatory markers in rat frontal cortex: Cross-talk between excitotoxicity and neuroinflammation. Neurochemical Research, 33, 2318-2323.
doi:10.1007/s11064-008-9731-8
|
[15]
|
Val’dman, E.A. (2001) Application-specific protocol. FSBI Zakusov Institute of Pharmacology, Moscow.
|
[16]
|
Wober, W. (1999) Comparative efficacy and safety of nimesulide and diclofenac in patients with acute shoulder, and a meta-analysis of controlled studies of nimesulide. Rheumatology (Oxford), 38, 33-38.
doi:10.1093/rheumatology/38.suppl_1.33
|
[17]
|
Caldwell, J.R. (1986) Efficacy and safety of diclofenac sodium in rheumatoid arthritis experience in the United States. The American Journal of Medicine, 80, 43-47.
|
[18]
|
Akriviadis, E., Hatzigavriel, M., Kapnias, D., Kirimlidis, J., Markantas, A. and Garyfallos, A. (1997) Treatment of biliary colic with diclofenac: A randomized, double-blind, placebo-controlled study. Gastroenterology, 113, 225-231.
doi:10.1016/S0016-5085(97)70099-4
|
[19]
|
Jorge, L.L., Feres, C.C. and Teles, V.E. (2011) Topical preparations for pain relief: Efficacy and patient adherence. Journal of Pain Research, 4, 11-24.
|
[20]
|
Davies, N.M. and Anderson, K.E. (1997) Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clinical Pharmacokinetics, 33, 184-213.
doi:10.2165/00003088-199733030-00003
|
[21]
|
Henry, D., Lim, L.L., Garcia Rodriguez, L.A., Perez Gutthann, S., Carson, J.L., Griffin, M., et al. (1996) Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis. British Medical Journal, 312, 1563-1566. doi:10.1136/bmj.312.7046.1563
|
[22]
|
Laporte, J., Ibanez, L., Vidal, X., Vendrell, L. and Leone, R. (2004) Upper gastrointestinal bleeding associated with the use of NSAIDs: Newer versus older agents. Drug safety, 27, 411-420.
doi:10.2165/00002018-200427060-00005
|
[23]
|
Shvarts, G.Ya. and Syabaev, R.D. (2005) Methodological instructions on the study of new nonsteroidal anti-inflammatory drugs. In: Chabriev, R.U. Ed., Guidance on experimental (preclinical) study of new pharmacological substances, Meditsina Publishers, Moscow, 695-709.
|
[24]
|
Bhandage, A., Shevkar, K. and Undale, V. (2009) Evaluation of antinociceptive activity of roots of Glycyrrhiza glabra Linn. Journal of Pharmacy Research, 2, 803-807.
|
[25]
|
Barkatullah, Ibrar, M., Ali, N., Muhammad, N. and Ehsan, M. (2012) In-vitro pharmacological study and preliminary phytochemical profile of Viola canescens Wall. Ex Roxb. African Journal of Pharmacy and Pharmacology, 6, 1142 -1146. doi:10.5897/AJPP12.061
|
[26]
|
Purnima, A., Koti, B.C., Thippeswamy, A.H.M., Jaji, M.S., Vishwantha Swamy, A.H.M., Kurhe, Y.V., et al. (2010) Antiinflammatory, analgesic and antipyretic activities of Mimusops elengi Linn. Indian Journal of Pharmaceutical Sciences, 72, 480-485.
doi:10.4103/0250-474X.73908
|
[27]
|
Ivanova, E., Nepoklonov, A., Kokshenev, I., Kapitsa, I., Voronina, T. and Val’dman, E. (2012) Study of anticataleptic activity of hemantane using different routs of drug administration and in combination with levodopa. Biomedicine, 1, 74-81.
|
[28]
|
Castrano, A., Hererra, A.J., Cano, J., and Machado, A. (1998) Lipopolysaccharide intranigral injection induces inflammatory reaction damage in nigrostriatal dopaminergic system. Journal of Neurochemistry, 70, 1584-1592.
doi:10.1046/j.1471-4159.1998.70041584.x
|
[29]
|
Bures, J., Petran, M. and Zachar, J. (1960) Electrophysiological methods in biological research. Academic Press, New York.
|
[30]
|
Schallert, T. and Jones, T.A. (1993) “Exuberant” neuronal growth after brain damage in adult rats: The essential role of behavioral experience. Journal of Neural Transplantation & Plasticity, 4, 193-198.
doi:10.1155/NP.1993.193
|
[31]
|
Kapitsa, I., Ivanova, E., Nepoklonov, A., Kokshenev, I., Voronina, T. and Val’dman, E. (2011) Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome. Eksperimental’naia I Klinicheskaia Farmakologiia, 7, 9-12.
|
[32]
|
Schallert, T., Fleming, S.M., Leasure, J.L., Tillerson, J.L. and Bland, S.T. (2000) CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology, 39, 777-787.
doi:10.1016/S0028-3908(00)00005-8
|
[33]
|
Kirik, D., Rosenblad, C., Bjorklund, A. and Mandel, R.J. (2000) Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson’s model: Intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. The Journal of Neuroscience, 20, 4686-4700.
|
[34]
|
Lemasson, M., Delbe, C., Gheusi, G., Vincent, J.D. and Lledo, P.M. (2005) Use of ultrasonic vocalizations to assess olfactory detection in mouse pups treated with 3- methylindole. Behavioural Processes, 68, 13-23.
doi:10.1016/j.beproc.2004.09.001
|
[35]
|
Liu, Y., Qin, L., Li, G., Zhang, W., An, L., Liu, B., et al. (2003) Dextromethorplan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. The Journal of Pharmacology and Experimental Therapeutics, 305, 212-218.
doi:10.1124/jpet.102.043166
|
[36]
|
Lam, F.F.Y. and Ng, E.S.K. (2010) Substance P and glutamate receptor antagonists improve the antiarthritic actions of dexamethasone in rats. British Journal of Pharmacology, 159, 958-969.
doi:10.1111/j.1476-5381.2009.00586.x
|
[37]
|
Fiebich, B.L., Schleicher, S., Spleiss, O., Czygan, M. and Hüll, M. (2001) Neuroinflammatory circuits in Alzheimer’s disease: Interleukin-1 induces cyclooxygenase 2 in human neuroblastoma cells. Proceedings of Meeting of the Volkswagen Foundation and the GEBIN on Psycho Neuro Endocrino Immunology, Regensburg, 15-17 November 2001, 15-16.
|
[38]
|
Ofman, J.J., MacLean, C.H., Straus, W.L., Morton, S.C., Berger, M.L., Roth, E.A., et al. (2002) A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. The Journal of Rheumatology, 29, 804-812.
|
[39]
|
Gao, H.M., Jiang, J., Wilson, B., Zhang, W., Hong, J.S. and Liu, B. (2002) Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: Relevance to Parkinson’s disease. Journal of Neurochemistry, 81, 1285-1297.
doi:10.1046/j.1471-4159.2002.00928.x
|
[40]
|
Iravani, M.M., Leung, C.C., Sedeghian, M., Haddon, C.O., Rose, S. and Jenner, P. (2005) The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. European Journal of Neuroscience, 22, 317-330.
doi:10.1111/j.1460-9568.2005.04220.x
|
[41]
|
Wisse, B.E., Ogimoto, K., Tang, J., Harris, M.K.J., Raines, E.W. and Schwartzm, M.W. (2007) Evidence that LPS-induced anorexia depends upon central, rather than peripheral, inflammatory signals. Endocrinology, 148, 5230-5237.doi:10.1210/en.2007-0394
|
[42]
|
Tolosa, E., Gaig, C., Santamaria, J. and Compta, Y. (2009) Diagnosis and the premotor phase of Parkinson disease. Neurology, 72, S12-S20.
doi:10.1212/WNL.0b013e318198db11
|
[43]
|
Tolosa, E., Compta, Y. and Gaig, C. (2007) The premotor phase of Parkinson’s disease. Parkinsonism & Related Disorders, 13, S2-S7.
doi:10.1016/j.parkreldis.2007.06.007
|
[44]
|
Hawkes, C.H., Shephard, B.C. and Daniel, S.E. (1999) Is Parkinson’s disease a primary olfactory disorder? International Journal of Medicine, 56, 33-39.
|
[45]
|
Tissingh, G., Berendse, H.W., Bergmans, P., DeWaard, R., Drukarch B., Stoof, J.C., et al. (2001) Loss of olfaction in de novo and treated Parkinson’s disease: Possible implications for early diagnosis. Movement Disorders, 6, 41-46.
doi:10.1002/1531-8257(200101)16:1<41::AID-MDS1017>3.0.CO;2-M
|
[46]
|
Müller, A., Reichmann, H., Livermore, A. and Hummel, T. (2002) Olfactory function in idiopathic Parkinson’s disease (IPD): Results from cross-sectional studies in IPD patients and long-term follow-up of de novo IPD patients. Journal of Neural Transmission, 109, 805-811.
doi:10.1007/s007020200067
|
[47]
|
Pearce, R.K.B., Hawkes, C.H. and Daniel, S.E. (1995) The anterior olfactory nucleus in Parkinson’s disease. Movement Disorders, 10, 283-287.
doi:10.1002/mds.870100309
|
[48]
|
Sobel, N., Thomason, M.E., Stappen, I., Tanner, C.M., Tetrud, J.W., Bower, J.M., et al. (2011) An impairment in sniffing contributes to the olfactory impairment in Parkinson’s disease. Proceedings of the National Academy of Sciences of the United States of America, 98, 4154-4159.
doi:10.1073/pnas.071061598
|
[49]
|
Aguilar, E., Mullol, J., Clementi, V., Perez, V. and Marin C. (2011) Odor discrimination impairment in 6-OHDA- lesioned rats: A tool for hyposmia research in Parkinson’s disease. Neurodegenerative Diseases, 8.
|
[50]
|
Furuyashiki, T., Holland, P.C. and Gallagher, M. (2008) Rat orbitofrontal cortex separately encodes response and outcome information during performance of goal-directed behavior. The Journal of Neuroscience, 28, 5127-5138.
doi:10.1523/JNEUROSCI.0319-08.2008
|